Status:
COMPLETED
Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms
Lead Sponsor:
Allergan
Conditions:
Dry Eye Syndromes
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study evaluates the performance and acceptance of Optive versus Hylocomod eyedrops, when administered for one month to patients with mild to moderate dry eye symptoms, with and without contact le...
Eligibility Criteria
Inclusion
- 18 years or over
- Contact lens wearer, spectacle wearer or non-spectacle wearer
- Mild to severe dry eye symptoms, defined as OSDI score 13 to 100
- Mild to moderate conjunctival staining in each eye and/or mild to moderate corneal staining in each eye
- Best corrected visual acuity of 6/9 in each eye
Exclusion
- Previously used Hylocomod or Optive eyedrops
- Systemic allergy or eye allergy
- Systemic disease which might have an ocular component and/or interfere with contact lens wear
- Autoimmune disease which might have an ocular component and/or interfere with contact lens wear
- Systemic medication which might have eye side effects and or interfere with contact lens wear
- Eye infection or use of eye medication
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00761202
Start Date
August 1 2007
End Date
June 1 2008
Last Update
November 19 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
London, London, United Kingdom